Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2020-12-10 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
유상증자최종발행가액확정
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the finalization of the issue price for a capital increase (paid-in capital increase/rights offering) for the company Genome & Company. It specifies the number of shares, the final price per share, and the date of determination. This falls under the category of share issuance and capital changes.
2020-12-10 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고서' (Amendment to Securities Registration Statement) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the public offering price (공모가액 확정) for Genome & Company. This type of regulatory filing is used to update previously submitted registration statements regarding capital raising activities. Since it is a formal regulatory filing related to a capital increase/share issuance, it falls under the 'Regulatory Filings' category as the most appropriate classification for this specific type of Korean financial disclosure.
2020-12-10 Korean
[기재정정]투자설명서
Investor Presentation Classification · 95% confidence The document is a '정정신고(보고)' (Amendment Report) for an '투자설명서' (Prospectus) filed by Genome & Company. It details changes to the offering price (from a range of 36,000-40,000 KRW to a fixed price of 40,000 KRW) and related financial figures for an IPO. In the context of financial filings, a prospectus amendment related to capital raising and share issuance is classified under 'Capital/Financing Update'.
2020-12-10 Korean
투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) for Genome & Company, dated December 7, 2020. It contains detailed information regarding a public offering of 2,000,000 shares, including offering price, subscription periods, risk factors, and business descriptions. In the context of financial filings, a prospectus is a formal document provided to potential investors to disclose information about a security offering. Among the provided categories, 'Proxy Solicitation & Information Statement' (PSI) is the closest fit for a document that provides detailed information to stakeholders/investors regarding a specific corporate action or offering, although it is technically a Prospectus. Given the options, it is classified as a Proxy Solicitation & Information Statement (PSI) as it serves to inform and solicit investment interest.
2020-12-07 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 100% confidence The document is a short, structured announcement reporting the results of an Investor Relations (IR) event held on 2020-11-20. It provides details such as the time, location, attendees, and a link to the IR materials. Since it is a brief notification regarding the occurrence of an event and the availability of materials rather than the presentation itself, it falls under the category of a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of reporting the outcome of an IR event, RPA is the most accurate classification.
2020-11-20 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a decision on a paid-in capital increase (유상증자결정) for Genome & Company. It explicitly states it is a 'Correction Report' (정정신고) for a previously filed document, detailing changes to the subscription schedule, payment dates, and related procedural details for a public offering. This falls under the category of capital and financing updates.
2020-11-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.